Globeflex Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Globeflex Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-27,416	Closed	-$1.37M	–	581
2016 Q4	$1.37M	Hold	27,416	–	–	0.34%	100
2016 Q3	$1.44M	Sell	27,416 -125	-0.5%	-$5.97K	0.36%	76
2016 Q2	$1.14M	Buy	27,541 +3,516	+15%	+$153K	0.31%	113
2016 Q1	$976K	Hold	24,025	–	–	0.26%	135
2015 Q4	$997K	Sell	24,025 -8,500	-26%	-$285K	0.27%	143
2015 Q3	$501K	Buy	32,525 +32,500	+130,000%	+$698K	0.11%	284
2015 Q2	$1K	Hold	25	–	–	﹤0.01%	478
2015 Q1	$1K	Buy	+25	New	+$631	﹤0.01%	496
2014 Q3	–	Sell	-83	Closed	-$1K	–	686
2014 Q2	$1K	Buy	+83	New	+$1.19K	﹤0.01%	547

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Globeflex Capital's FPRX Position: Q1 2017 in Review

Globeflex Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 27,416 shares — an estimated $1.37M sold.

Globeflex Capital first reported a position in FPRX in Q2 2014 and held it in 9 quarters. The position peaked at $1.44M in Q3 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

Globeflex Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Globeflex Capital sold 27,416 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $1.37M.
Globeflex Capital first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 9 quarters.
Globeflex Capital's Five Prime Therapeutics, Inc. position peaked at $1.44M in Q3 2016.
157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.